Research Progress on the Synergistic Effects of Bifidobacterium and Portulaca oleracea L. in the Treatment of Ulcerative Colitis
Abstract
Ulcerative colitis (UC) is a chronic, nonspecific inflammatory bowel disease with complex causes. Current treatments have limited success in maintaining long-term remission and may raise safety concerns. Portulaca oleracea L. (POL), a traditional Chinese medicinal herb, contains active compounds such as quercetin, flavonoids, and γ-linolenic acid, which work through multiple targets and pathways to reduce inflammation, repair the mucosal barrier, and regulate immunity. At the same time, Bifidobacterium, a major probiotic in the gut, helps manage UC by adjusting the microbial composition, strengthening the intestinal barrier, and modulating immune responses. This article reviews recent studies on how POL and Bifidobacterium act in UC, summarizing their mechanisms and experimental evidence in terms of anti-inflammation, barrier repair, immune regulation, and microecological restoration. Further analysis suggests that these two agents may complement each other: POL helps create a better environment for Bifidobacterium to settle, while Bifidobacterium turns the early signals from POL into lasting effects. However, most current evidence comes from separate studies, and direct experiments testing their combined use are still missing. Future work should include animal studies with combined treatments, screening for the best strain combinations, and deeper mechanistic studies, so as to build a solid basis for using natural products and probiotics together in UC therapy.